Sugi Predict

Sugi Predict / Targets / ADA

ADA

Adenosine deaminase · P00813 · ADA on Sugi Atlas →

8,575 patent compounds predicted against ADA, 4,923 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4584009 SCHEMBL4584009 0.64 15/20
SCHEMBL4583746 SCHEMBL4583746 0.67 14/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1383461) 0.62 14/20
SCHEMBL4584798 SCHEMBL4584798 0.65 13/20
SCHEMBL4584393 SCHEMBL4584393 0.55 13/20
SCHEMBL4584354 SCHEMBL4584354 0.65 12/20
SCHEMBL4584344 SCHEMBL4584344 0.80 11/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4583903) 0.79 11/20
SCHEMBL4585448 SCHEMBL4585448 0.78 11/20
SCHEMBL4582650 SCHEMBL4582650 0.67 11/20
SCHEMBL4584138 SCHEMBL4584138 0.67 11/20
SCHEMBL4585439 SCHEMBL4585439 0.66 11/20
SCHEMBL1387063 SCHEMBL1387063 0.62 11/20
SCHEMBL4584977 SCHEMBL4584977 0.59 11/20
SCHEMBL4585451 SCHEMBL4585451 0.59 11/20
SCHEMBL4583376 SCHEMBL4583376 0.82 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4583534) 0.81 10/20
SCHEMBL4584972 SCHEMBL4584972 0.78 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4583770) 0.66 10/20
SCHEMBL4584642 SCHEMBL4584642 0.65 10/20

Clinical trials — most relevant to ADA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. PHASE4RECRUITING
Stress Testing and Cardiac Magnetic Resonance PHASE4COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine PHASE3COMPLETED
Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes PHASE3UNKNOWN
EZN-2279 in Patients With ADA-SCID PHASE3COMPLETED
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector PHASE1/PHASE2RECRUITING
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID PHASE2COMPLETED
Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia PHASE2COMPLETED
Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency PHASE1/PHASE2COMPLETED
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector PHASE1COMPLETED
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency PHASE1COMPLETED
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML PHASE1UNKNOWN
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Phase I, Dose Escalation Study of Decitabine PHASE1COMPLETED
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients EARLY_PHASE1RECRUITING
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA) nanUNKNOWN
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis nanUNKNOWN
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E nanUNKNOWN
Regulation of Vascular Thrombosis in Sleep Apnea nanCOMPLETED
Investigation of ADA Enzyme Deficiency nanUNKNOWN
Polymorphisms, Caffeine and Sleep Disorders nanCOMPLETED
An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID nanENROLLING_BY_INVITATION
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) nanUNKNOWN
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID nanRECRUITING
A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS) nanUNKNOWN
Comparative Safety Study of Two Vaginal Applicators With Tenofovir nanCOMPLETED
Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes nanCOMPLETED
Role of Type 2 Diabetes in Potentiating the Inflammatory Response Post Extracorporeal Circulation After Cardiac Surgery nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a ADA binder may also engage these)

ProteinNameSimilarity
P03958 — 0.998 P03958 →
P56658 — 0.995 P56658 →
Q920P6 — 0.995 Q920P6 →
Q63ZU0 — 0.987 Q63ZU0 →
Q6GP70 — 0.986 Q6GP70 →
Q6DG22 — 0.986 Q6DG22 →
Q5ZKP6 — 0.983 Q5ZKP6 →
Q4V831 — 0.977 Q4V831 →
Q80SY6 — 0.973 Q80SY6 →
Q6DHV7 — 0.972 Q6DHV7 →
Q0VC13 — 0.971 Q0VC13 →
Q14194 — 0.970 Q14194 →
Q62952 — 0.970 Q62952 →
P51018 — 0.970 P51018 →
Q62950 — 0.970 Q62950 →
Q4V9P6 — 0.970 Q4V9P6 →
P80402 — 0.969 P80402 →
Q62188 — 0.968 Q62188 →
Q8LPL7 — 0.968 Q8LPL7 →
Q47B13 — 0.967 Q47B13 →
Q5R9Y6 — 0.967 Q5R9Y6 →
DPYSL2 Dihydropyrimidinase-related protein 2 0.967 landscape →
P51014 — 0.966 P51014 →
O02675 — 0.966 O02675 →
O13022 — 0.966 O13022 →
P47942 — 0.966 P47942 →
Q90635 — 0.965 Q90635 →
Q6CM42 — 0.965 Q6CM42 →
O35098 — 0.965 O35098 →
Q55664 — 0.965 Q55664 →